MCKECHNIE DUNCAN (EVP, Chief Commercial Officer) sold 21.9% of their position (4.91K shares) of VERTEX PHARMACEUTICALS INC / MA on the open market
Open‑market sale worth $2.39M — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 2/26/2026ACC: 0000875320-26-000116
Officer· EVP, Chief Commercial Officer
Since Mar 2026
-5.78K
Net shares
Net seller
$2.82M
Total sold
2
Open market trades
0B · 2S
3
Total transactions
5.78K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−873.00
Price / share
$485.11
Trade value
$423.50K
% of position
3.7%
2/24/2026
23.34K→22.47K
Common Stock
Direct
Shares
−2.50K
Price / share
$486.35
Trade value
$1.22M
% of position
11.1%
2/25/2026
22.47K→19.97K
Common Stock
Direct
Shares
−2.41K
Price / share
$489.00
Trade value
$1.18M
% of position
12.1%
2/25/2026
19.97K→17.56K
Total
Net shares
−5.78K
Net value
-$2.82M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/24/2026 | F · Tax Withholding | −873.00 | $485.11 | $423.50K | 3.7% | 23.34K | 22.47K |
| Common Stock Direct | 2/25/2026 | S · Sale | −2.50K | $486.35 | $1.22M | 11.1% | 22.47K | 19.97K |
| Common Stock Direct | 2/25/2026 | S · Sale | −2.41K | $489.00 | $1.18M | 12.1% | 19.97K | 17.56K |
| Total | −5.78K | -$2.82M | ||||||
Derivative Transactions0
No derivative transactions reported